Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Expectations By $0.06 EPS

Lucid Diagnostics (NASDAQ:LUCD) announced its quarterly earnings data on Monday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.06), Zacks reports.

Lucid Diagnostics Price Performance

Shares of LUCD stock opened at $1.48 on Monday. Lucid Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $1.63. The stock’s 50-day moving average is $1.20 and its two-hundred day moving average is $0.98. The firm has a market cap of $87.83 million, a P/E ratio of -1.29 and a beta of 1.34.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets cut their price objective on shares of Lucid Diagnostics from $7.25 to $7.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $3.63.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.